Section of Epidemiology and Population Sciences, Department of Medicine, and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):432-443. doi: 10.1038/s41575-021-00419-3. Epub 2021 Feb 18.
Oesophageal cancer is a global health problem; in 2018 there were more than 572,000 people newly diagnosed with oesophageal cancer worldwide. There are two main histological subtypes of oesophageal cancer, oesophageal adenocarcinoma (EAC) and oesophageal squamous cell carcinoma (ESCC), and there has been a dramatic shift in its epidemiology. While the incidence of EAC and its precursor lesion, Barrett oesophagus, has increased in Western populations over the past four decades, the incidence of ESCC has declined in most parts of the world over the same period. ESCC still accounts for the vast majority of all oesophageal cancer cases diagnosed worldwide each year. Prognosis for patients with oesophageal cancer is strongly related to stage at diagnosis. As most patients are diagnosed with late-stage disease, overall 5-year survival for oesophageal cancer remains <20%. Knowledge of epidemiology and risk factors for oesophageal cancer is essential for public health and clinical decisions about risk stratification, screening and prevention. The goal of this Review is to establish the current epidemiology of oesophageal cancer, with a particular focus on the Western world and the increasing incidence of EAC and Barrett oesophagus.
食管癌是一个全球性的健康问题;2018 年,全球有超过 57.2 万人被新诊断为食管癌。食管癌有两种主要的组织学亚型,食管腺癌(EAC)和食管鳞状细胞癌(ESCC),其流行病学特征发生了显著变化。在过去的四十年中,西方人群中 EAC 及其前体病变 Barrett 食管的发病率有所增加,而与此同时,世界上大多数地区的 ESCC 发病率却有所下降。ESCC 仍然占全球每年诊断出的所有食管癌病例的绝大多数。食管癌患者的预后与诊断时的分期密切相关。由于大多数患者被诊断为晚期疾病,食管癌的总体 5 年生存率仍<20%。了解食管癌的流行病学和危险因素对于公共卫生以及关于风险分层、筛查和预防的临床决策至关重要。本综述的目的是确定食管癌的当前流行病学情况,特别关注西方世界以及 EAC 和 Barrett 食管发病率的上升。
Nat Rev Gastroenterol Hepatol. 2021-6
Scand J Gastroenterol Suppl. 2001
World J Gastroenterol. 2017-7-28
Nat Rev Gastroenterol Hepatol. 2014-5-27
Dig Liver Dis. 2013-2-28
Korean J Helicobacter Up Gastrointest Res. 2025-3
Front Cell Dev Biol. 2025-5-30
Nat Rev Cancer. 2019-12-17
Clin Gastroenterol Hepatol. 2020-11
Am J Gastroenterol. 2020-2
Am J Gastroenterol. 2019-6
Aliment Pharmacol Ther. 2019-4-4